TY - JOUR
T1 - Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of β1-integrin and phosphatidylinositol 3′-kinase/AKT signaling
AU - Tai, Yu-Tzu
AU - Podar, Klaus
AU - Catley, Laurence
AU - Tseng, Yu-Hua
AU - Akiyama, Masaharu
AU - Shringarpure, Reshma
AU - Burger, Renate
AU - Hideshima, Teru
AU - Chauhan, Dharminder
AU - Mitsiades, Nicholas
AU - Richardson, Paul
AU - Munshi, Nikhil C
AU - Kahn, C Ronald
AU - Mitsiades, Constantine
AU - Anderson, Kenneth C
PY - 2003/9/15
Y1 - 2003/9/15
N2 - Insulin-like growth factor-1 (IGF-I) is a growth and survival factor in human multiple myeloma (MM) cells. Here we examine the effect of IGF-I on MM cell adhesion and migration, and define the role of β1 integrin in these processes. IGF-I increases adhesion of MM.1S and OPM6 MM cells to fibronectin (FN) in a time- and dose-dependent manner, as a consequence of IGF-IR activation. Conversely, blocking anti-β1 integrin monoclonal antibody, RGD peptide, and cytochalasin D inhibit IGF-I-induced cell adhesion to FN. IGF-I rapidly and transiently induces association of IGF-IR and β1 integrin, with phosphorylation of IGF-IR, IRS-1, and p85
PI3-K. IGF-I also triggers phosphorylation of AKT and ERK significantly. Both IGF-IR and β1 integrin colocalize to lipid rafts on the plasma membrane after IGF-I stimulation. In addition, IGF-I triggers polymerization of F-actin, induces phosphorylation of p125
FAK and paxillin, and enhances β1 integrin interaction with these focal adhesion proteins. Importantly, using pharmacological inhibitors of phosphatidylinositol 3′-kinase (PI3-K) (LY294002 and wortmannin) and extracellular signal-regulated kinase (PD98059), we demonstrate that IGF-I-induced MM cell adhesion to FN is achieved only when PI3-K/AKT is activated. IGF-I induces a 1.7-2.2 (MM.1S) and 2-2.5-fold (OPM6) increase in migration, whereas blocking anti-IGF-I and anti-β1 integrin monoclonal antibodies, PI3-K inhibitors, as well as cytochalasin D abrogate IGF-I-induced MM cell transmigration. Finally, IGF-I induces adhesion of CD138+ patient MM cells. Therefore, these studies suggest a role for IGF-I in trafficking and localization of MM cells in the bone marrow microenvironment. Moreover, they define the functional association of IGF-IR and β1 integrin in mediating MM cell homing, providing the preclinical rationale for novel treatment strategies targeting IGF-I/IGF-IR in MM.
AB - Insulin-like growth factor-1 (IGF-I) is a growth and survival factor in human multiple myeloma (MM) cells. Here we examine the effect of IGF-I on MM cell adhesion and migration, and define the role of β1 integrin in these processes. IGF-I increases adhesion of MM.1S and OPM6 MM cells to fibronectin (FN) in a time- and dose-dependent manner, as a consequence of IGF-IR activation. Conversely, blocking anti-β1 integrin monoclonal antibody, RGD peptide, and cytochalasin D inhibit IGF-I-induced cell adhesion to FN. IGF-I rapidly and transiently induces association of IGF-IR and β1 integrin, with phosphorylation of IGF-IR, IRS-1, and p85
PI3-K. IGF-I also triggers phosphorylation of AKT and ERK significantly. Both IGF-IR and β1 integrin colocalize to lipid rafts on the plasma membrane after IGF-I stimulation. In addition, IGF-I triggers polymerization of F-actin, induces phosphorylation of p125
FAK and paxillin, and enhances β1 integrin interaction with these focal adhesion proteins. Importantly, using pharmacological inhibitors of phosphatidylinositol 3′-kinase (PI3-K) (LY294002 and wortmannin) and extracellular signal-regulated kinase (PD98059), we demonstrate that IGF-I-induced MM cell adhesion to FN is achieved only when PI3-K/AKT is activated. IGF-I induces a 1.7-2.2 (MM.1S) and 2-2.5-fold (OPM6) increase in migration, whereas blocking anti-IGF-I and anti-β1 integrin monoclonal antibodies, PI3-K inhibitors, as well as cytochalasin D abrogate IGF-I-induced MM cell transmigration. Finally, IGF-I induces adhesion of CD138+ patient MM cells. Therefore, these studies suggest a role for IGF-I in trafficking and localization of MM cells in the bone marrow microenvironment. Moreover, they define the functional association of IGF-IR and β1 integrin in mediating MM cell homing, providing the preclinical rationale for novel treatment strategies targeting IGF-I/IGF-IR in MM.
KW - Antibodies, Monoclonal/pharmacology
KW - Cell Adhesion/drug effects
KW - Cell Line, Tumor
KW - Cell Movement/drug effects
KW - Enzyme Activation
KW - Fibronectins/metabolism
KW - Humans
KW - Insulin-Like Growth Factor I/antagonists & inhibitors
KW - Integrin beta1/metabolism
KW - Membrane Glycoproteins/metabolism
KW - Membrane Microdomains/metabolism
KW - Mitogen-Activated Protein Kinase 1/antagonists & inhibitors
KW - Mitogen-Activated Protein Kinase 3
KW - Mitogen-Activated Protein Kinases/antagonists & inhibitors
KW - Multiple Myeloma/enzymology
KW - Oligopeptides/pharmacology
KW - Phosphatidylinositol 3-Kinases/metabolism
KW - Phosphoinositide-3 Kinase Inhibitors
KW - Protein Serine-Threonine Kinases
KW - Proteoglycans/metabolism
KW - Proto-Oncogene Proteins/metabolism
KW - Proto-Oncogene Proteins c-akt
KW - Receptor Cross-Talk/physiology
KW - Receptor, IGF Type 1/metabolism
KW - Signal Transduction/physiology
KW - Syndecan-1
KW - Syndecans
UR - https://www.scopus.com/pages/publications/0141731299
M3 - Journal article
C2 - 14522909
SN - 0008-5472
VL - 63
SP - 5850
EP - 5858
JO - Cancer Research
JF - Cancer Research
IS - 18
ER -